Harmony Biosciences Holdings, Inc. business relationships
Companies named in Harmony Biosciences Holdings, Inc.’s 10-K filed 2026-02-24, and public companies whose annual reports name Harmony Biosciences Holdings, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 1% in its category
- Agent readiness
- 20 / 100
- AI adoption
- 0 / 100
Named in Harmony Biosciences Holdings, Inc.’s annual report 3
“For the year ended December 31, 2025, three customers accounted for 100 % of gross product revenue; CVS Caremark accounted for 38 % of gross product revenue; Accredo accounted for 36 % of gross product revenue; and PANTHERx accounted for 26 % of gross product revenue.” SEC filing
“In September 2023, the Company and its licensor, Bioprojet, received notice from Lupin Limited ("Lupin") pursuant to 21 U.S.C. § 355(j) et seq. and 21 C.F.R. § 314.95 et seq. (the "Lupin Notice Letter") that Lupin has submitted ANDA No. 218846 (the "Lupin ANDA") to the FDA and is seeking regulatory...” SEC filing
“In June 2025, we entered into a research collaboration, option and license agreement (the "CiRC Agreement") with CiRC Biosciences, Inc. ("CiRC"), a related party.” SEC filing
Companies whose annual reports name Harmony Biosciences Holdings, Inc. 1
“...with narcolepsy have available to them a variety of medications, such as generic and/or branded forms of Xyrem and Xywav, which are marketed by Jazz; Wakix, which is marketed by Harmony Biosciences LLC; Lumryz, which is marketed by Alkermes plc; Provigil and Nuvigil, which are manufactured by Teva.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.